Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.
Sun Y, Zhang W, Bi X, Yang Z, Tang Y, Jiang L, Bi F, Chen M, Cheng S, Chi Y, Han Y, Huang J, Huang Z, Ji Y, Jia L, Jiang Z, Jin J, Jin Z, Li X, Li Z, Liang J, Liu L, Liu Y, Lu Y, Lu S, Meng Q, Niu Z, Pan H, Qin S, Qu W, Shao G, Shen F, Song T, Song Y, Tao K, Tian A, Wang J, Wang W, Wang Z, Wu L, Xia F, Xing B, Xu J, Xue H, Yan D, Yang L, Ying J, Yun J, Zeng Z, Zhang X, Zhang Y, Zhang Y, Zhao J, Zhou J, Zhu X, Zou Y, Dong J, Fan J, Lau WY, Sun Y, Yu J, Zhao H, Zhou A, Cai J. Sun Y, et al. Among authors: qu w. Liver Cancer. 2022 Jan 4;11(3):192-208. doi: 10.1159/000521596. eCollection 2022 Jun. Liver Cancer. 2022. PMID: 35949289 Free PMC article. Review.
Dynamic alteration and prognostic significance of tumor-associated CD68+ and CD68+ PD-L1- macrophages in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy.
Wu J, Xie RY, Wei LH, Cao CZ, Shang BQ, Guan YY, Shi HZ, Qu W, Li Y, Liang J, Zheng S, Zhou AP, Zhou XF, Shou JZ, Bi XG. Wu J, et al. Among authors: qu w. Cancer Med. 2023 Feb;12(4):4981-4992. doi: 10.1002/cam4.5191. Epub 2022 Aug 31. Cancer Med. 2023. PMID: 36043478 Free PMC article.
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
Li Y, Zhou A, Liu S, He M, Chen K, Tian Z, Li Y, Qin J, Wang Z, Chen H, Tian H, Yu Y, Qu W, Xue L, He S, Wang S, Bie F, Bai G, Zhou B, Yang Z, Huang H, Fang Y, Li B, Dai X, Gao S, He J. Li Y, et al. Among authors: qu w. BMC Med. 2023 Mar 8;21(1):86. doi: 10.1186/s12916-023-02804-y. BMC Med. 2023. PMID: 36882775 Free PMC article. Clinical Trial.
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
Zhang W, Zhou H, Jiang J, Zhu Y, Zou S, Jiang L, Tang Y, Liang J, Sun Y, Jiang Z, Qu W, Li Y, Zhou A. Zhang W, et al. Among authors: qu w. BMC Cancer. 2023 Jun 27;23(1):592. doi: 10.1186/s12885-023-11103-x. BMC Cancer. 2023. PMID: 37370032 Free PMC article. Clinical Trial.
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma.
Qu W, Fu C, Han W, Luo H, Quan J, Chen L, Liao Y, Hu C, Hu H, Niu Y, Xu D, Chen M, Chen J, Liu Y, Chen G, Luo Z, Shi B, Sun Y, Zhou F, Zhou A. Qu W, et al. Eur J Cancer. 2024 Jul;205:114096. doi: 10.1016/j.ejca.2024.114096. Epub 2024 May 10. Eur J Cancer. 2024. PMID: 38772302 Clinical Trial.
2,371 results